查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球子宫癌市场评估：按类型、方式、最终用户、地区、机会、预测（2017-2031）
市场调查报告书
商品编码
1417603

全球子宫癌市场评估：按类型、方式、最终用户、地区、机会、预测（2017-2031）

Uterine Cancer Market Assessment, By Types, By Modality, By End-users, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 230 Pages | 商品交期: 3-5个工作天内

价格

预计2023年全球子宫癌市场规模将达260.5亿美元，2031年将达386.3亿美元，2024-2031年预测期间复合年增长率为5.05%。全球子宫癌市场受到许多市场驱动因素的影响。这是由于子宫癌盛行率不断上升、筛检和诊断技术的进步、研究关注的增加、新的治疗方法、对意识和教育的关注、人口老化的影响，其中包括政府主导的计划和政策。

子宫癌发生率的增加是全球子宫癌市场的主要成长动力。这一趋势很大程度上是由于肥胖、生活方式的改变以及人口老化的增加等因素所造成的。随着被诊断的患者数量不断增加，对有效筛检、诊断和治疗方案的需求也在增加。筛检和诊断技术的进步在早期检测中发挥着至关重要的作用，并有助于改善患者的预后。超音波、MRI 和微创技术等方式正在彻底改变子宫癌的诊断和治疗方式，使医疗保健专业人员能够更早发现疾病。标靶治疗、免疫疗法和精准医学等新方法越来越受欢迎。

老年人数量的增加导致子宫癌的风险增加，因为停经后妇女特别容易受到伤害。政府措施和政策对于塑造全球子宫癌市场至关重要。这包括资助研究、获得医疗服务以及製定全面的癌症治疗计划。临床试验和正在进行的科学研究对于发现创新的治疗方案和治疗方法至关重要。患者权益团体正在利用其影响力来提高意识、提供支持并倡导增加获得护理和治疗的机会。他们的工作有助于创造一个让患者获得超越医疗照护的全面照护和支持的环境。

子宫癌盛行率上升

子宫癌盛行率的增加在推动全球子宫癌市场方面发挥关键作用。根据 BMC Women's Health 的数据，2020 年全球估计有 417,000 例新诊断子宫癌病例，呈现令人不安的上升趋势。2022年，美国将有超过65,000名子宫内膜癌患者被诊断出来。值得注意的是，40 岁以下女性的子宫癌发生率增加了一倍，这凸显了年轻族群需要更有效的筛检和治疗方案。在美国，预计到 2023 年，子宫癌将成为新病例中第四大常见癌症，以及女性癌症相关死亡的第六大原因。解决子宫癌发病率和死亡率不断上升的问题凸显了继续研究、改善诊断工具和开创性治疗进展的迫切需求。早期发现、宣传活动以及大力发展治疗方法是有效应对这项公共卫生挑战的关键要素。

加大对研究的关注

全球子宫癌市场的成长主要受到创新治疗研发投资增加的推动。这些投资加速了新疗法的发现和开发，从而改善患者的治疗结果和生活品质。研究工作正在有助于扩大治疗选择，包括标靶治疗和免疫疗法，并为子宫癌患者带来新的希望。此外，发现更有效治疗方法的研究将鼓励製药和生技公司投资于这些治疗方法的开发，推动市场成长并最终减少子宫癌，改善患者预后。

2023 年 10 月 密苏里大学医学院助理教授 Tae Hoon Kim 博士获得大笔资助。这笔为期五年的拨款总额为 226 万美元，由美国国立卫生研究院下属的Eunice Kennedy Shriver National Institute of Child Health and Human Development授予。Kim 博士的研究计画重点在于研究旨在保留患有子宫内膜增生的育龄妇女生育能力的治疗方法。

本报告研究和分析了全球子宫癌市场，提供市场规模和预测、市场动态、主要参与者趋势和前景等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章执行摘要

第四章全球子宫癌市场展望（2017-2031）

  • 市场规模及预测
    • 金钱数额
    • 数量
  • 按类型
    • 子宫内膜腺癌
    • 浆液性腺癌
    • 乳头状浆液性癌
    • 子宫肉瘤
    • 其他
  • 按方式
    • 诊断
    • 治疗
  • 按最终用户
    • 医院
    • 门诊手术中心
    • 专科诊所
    • 药店
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第五章全球子宫癌市场展望：按地区（2017-2031）

  • 北美
    • 市场规模及预测
    • 按类型
    • 按方式
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第六章 市场测绘（2023）

  • 按类型
  • 按阶段
  • 按组别
  • 按方式
  • 按最终用户
  • 按地区

第七章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第八章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第九章 监理架构与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新技术

第十章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）
  • 专利分析（如果适用）

第11章价格分析

第十二章案例研究

第十三章 主要公司展望

  • Novartis AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • AstraZeneca plc
  • Johnson & Johnson Innovative Medicine
  • Bayer AG
  • AbbVie Inc.
  • GSK plc
  • Eli Lilly and Company

第十四章 战略建议

第十五章 关于我们公司、免责声明

Product Code: MX10897

Global uterine cancer market size was valued at USD 26.05 billion in 2023, expected to reach USD 38.63 billion in 2031, with a CAGR of 5.05% for the forecast period between 2024 and 2031. The global uterine cancer market is subject to a multitude of factors that are driving the market. The contributing factors consist of rising prevalence of uterine cancer, advancements in screening and diagnostic technologies, increased focus on research, novel treatment approaches, focused initiatives on awareness and education, impact of aging population, and government-led programs and policies.

The increasing incidence of uterine cancer stands as a prominent driver for the growth of global uterine cancer market. The trend is largely attributed to factors like obesity, lifestyle changes, and rising aging population. As the number of diagnosed patients continues to rise, there is a growing demand for effective screening, diagnostic, and treatment options. Advancements in screening and diagnostic technologies play a pivotal role in early detection, aiding in better patient outcomes. Modalities such as ultrasound, MRI, and minimally invasive techniques have revolutionized the way uterine cancer is diagnosed and treated, enabling healthcare professionals to detect the disease at early stages. Novel approaches such as targeted therapies, immunotherapies, and precision medicine are gaining popularity.

Growing geriatric is contributing to the increased risk of uterine cancer, as postmenopausal women are particularly vulnerable. Government initiatives and policies are integral in shaping the global uterine cancer market. These include funding for research, access to healthcare services, and the development of comprehensive cancer care programs. Clinical trials and ongoing scientific research are essential for uncovering innovative treatment options and therapies. Patient advocacy groups exert influence, raising awareness, providing support, and advocating for enhanced care and treatment access. Their efforts contribute to an environment where patients receive comprehensive care and support beyond medical treatment.

Rising Prevalence of Uterine Cancer

The increasing prevalence of uterine cancer plays a pivotal role in driving the global uterine cancer market. According to BMC Women's Health, as of 2020, there were an estimated 417,000 new uterine cancer diagnoses worldwide, revealing a troubling upward pattern. In 2022, more than 65,000 endometrial cancer patients were diagnosed in the United States. Notably, the incidence of uterine cancer has doubled among women under the age of 40, underscoring the essential need for more efficient screening and treatment options for the younger demographic. In the United States, uterine cancer is anticipated to rank as the fourth most common cancer among new cases and the sixth leading cause of female cancer-related deaths in 2023. It highlights the urgent demand for ongoing research, improved diagnostic tools, and the advancement of pioneering therapies to address the rise in uterine cancer incidence and mortality rates. Vigorous efforts in early detection, awareness campaigns, and the evolution of treatment modalities are crucial components in effectively addressing this public health challenge.

Growing Focus on Research

The growth of the global uterine cancer market is significantly propelled by increasing investments in research and development efforts focused on innovative treatments. These investments drive the discovery and development of novel therapies, which can improve patient outcomes and quality of life. Research initiatives contribute to expanding treatment options, including targeted therapies and immunotherapies, offering new hope for uterine cancer patients. Furthermore, as research uncovers more effective treatments, it encourages pharmaceutical and biotechnology companies to invest in the development of these therapies, fostering market growth and ultimately enhancing the prognosis for those affected by uterine cancer.

In October 2023, Dr. Tae Hoon Kim, PhD, who serves as an assistant professor at the University of Missouri School of Medicine, received a substantial grant. The five-year grant, totaling USD 2.26 million, was awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health. Dr. Kim's research project focuses on investigating treatments aimed at preserving fertility in women of reproductive age who are affected by endometrial hyperplasia.

Government Initiatives

Governments globally are implementing initiatives to raise awareness about uterine cancer, recognizing its significance in public health. By promoting education and regular screenings, these campaigns aim to reduce the stigma associated with uterine cancer and encourage early detection. As awareness grows, more women are likely to seek timely medical attention, driving the demand for diagnostic and treatment services. It in turn, contributes to the expansion of global uterine cancer market, as healthcare providers and pharmaceutical companies respond to the increased demand, ultimately improving outcomes for patients through early intervention and effective treatments. In June 2023, Israel and other countries attended Endometrial Cancer Awareness Week to combat the lack of awareness among women and the insufficient funding allocated for the diagnosis and treatment of the condition.

Immunotherapy is Expected to Witness Significant Growth Over the Forecasted Period

The global uterine cancer market is witnessing a substantial uptick in the utilization of immunotherapy as a preferred treatment modality. Immunotherapy, a therapeutic approach that leverages the body's immune system to target and eliminate cancer cells, has displayed encouraging outcomes in the context of uterine cancer treatment. The growing demand for immunotherapy is primarily rooted in its potential to offer more effective and less invasive treatment alternatives, especially for cases at advanced or recurrent stages. Consequently, both pharmaceutical companies and research institutions are investing in the development of tailored immunotherapeutic agents for uterine cancer. The growing interest in immunotherapy stands as an important catalyst in the expansion of the global uterine cancer market.

In May 2023, the addition of Imfinzi plus Lynparza and Imfinzi alone resulted in notable enhancements in progression-free survival for individuals with advanced endometrial cancer when incorporated with chemotherapy. DUO-E marks the inaugural global Phase III trial where the combination of immunotherapy and PARP inhibition showcased substantial clinical advantages within this context.

Development of Novel Treatment Methods for High-Risk Uterine Cancer

High-risk uterine cancer typically presents with factors like advanced stage, aggressive histology, or recurring tumors, making it a formidable challenge for patients and healthcare providers. The increasing incidence of high-risk uterine cancer underscores the critical need for effective therapeutic interventions, including advanced surgical techniques, radiation therapy, targeted therapies, and immunotherapies. As these treatment options evolve and become more accessible, the growing demand to address high-risk uterine cancer becomes a driving force in the global healthcare market.

As an example, in February 2023, GSK plc disclosed that the US Food and Drug Administration (FDA) had issued complete approval for Jemperli (dostarlimab-gxly). The approval pertains to the treatment of adult patients dealing with recurrent or advanced endometrial cancer, specifically those characterized by a mismatch repair-deficiency (dMMR) as determined through an FDA-sanctioned test. These patients must have experienced disease progression after prior treatment with a platinum-based regimen in any therapeutic context who are not considered suitable candidates for curative surgical procedures or radiation therapy.

Future Market Scenario

The future of the global uterine cancer market looks promising, contributing to its overall growth. Several factors are driving growth in the market. Ongoing advancements in medical research and technology are continually expanding our understanding of uterine cancer, leading to the development of more targeted and effective treatment options. Increasing awareness and early detection efforts will likely reduce late-stage diagnoses, improving treatment outcomes. Additionally, the rising incidence of uterine cancer, driven by factors such as an aging population and lifestyle changes, creates a sustained demand for healthcare services. Furthermore, the emergence of innovative therapies, including immunotherapies and precision medicine, offers new avenues for treatment, giving hope to patients with limited options. The factors collectively ensure a promising trajectory for the global uterine cancer market, where research, innovation, and awareness campaigns converge to enhance patient care and drive market growth.

Key Players Landscape and Outlook

The global uterine cancer market is witnessing significant growth due to strategic collaborations among major pharmaceutical companies. These partnerships bring expertise, resources, and research capabilities together from multiple organizations to accelerate the development of innovative therapies and treatment approaches. The collaborations facilitate the combination of knowledge and technologies, resulting in faster drug discovery and development. They enable a more efficient response to the complex challenges posed by uterine cancer, ultimately benefiting patients by expanding treatment options and improving outcomes. The synergy among pharmaceutical companies spurs innovation and drives market expansion, meeting the growing demand for effective uterine cancer treatments.

In June 2022, Astellas and Sutro Biopharma revealed a global strategic partnership aimed at advancing innovative immunostimulatory antibody-drug conjugates (iADCs) for the treatment of uterine cancer. iADCs represents a cutting-edge therapeutic approach in uterine cancer treatment.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Uterine Cancer Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Types
    • 4.2.1. Endometroid Adenocarcinoma
    • 4.2.2. Serous Adenocarcinoma
    • 4.2.3. Papillary Serous Carcinoma
    • 4.2.4. Uterine Sarcoma
    • 4.2.5. Others
  • 4.3. By Modality
    • 4.3.1. Diagnosis
      • 4.3.1.1. CT scan
      • 4.3.1.2. MRI Scan
      • 4.3.1.3. PET Scan
      • 4.3.1.4. Blood Test
      • 4.3.1.5. Ultrasound
      • 4.3.1.6. Endometrial Biopsy
    • 4.3.2. Treatment
      • 4.3.2.1. Surgery
      • 4.3.2.2. Radiation Therapy
      • 4.3.2.3. Chemotherapy
      • 4.3.2.4. Immunotherapy
      • 4.3.2.5. Others
  • 4.4. By End-users
    • 4.4.1. Hospitals
    • 4.4.2. Ambulatory Surgical Centers
    • 4.4.3. Specialty Clinics
    • 4.4.4. Pharmacies
    • 4.4.5. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. South America
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Uterine Cancer Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Types
      • 5.1.2.1. Endometroid Adenocarcinoma
      • 5.1.2.2. Serous Adenocarcinoma
      • 5.1.2.3. Papillary Serous Carcinoma
      • 5.1.2.4. Uterine Sarcoma
      • 5.1.2.5. Others
    • 5.1.3. By Modality
      • 5.1.3.1. Diagnosis
      • 5.1.3.1.1. CT scan
      • 5.1.3.1.2. MRI Scan
      • 5.1.3.1.3. PET Scan
      • 5.1.3.1.4. Blood Test
      • 5.1.3.1.5. Ultrasound
      • 5.1.3.1.6. Endometrial Biopsy
      • 5.1.3.2. Treatment
      • 5.1.3.2.1. Surgery
      • 5.1.3.2.2. Radiation Therapy
      • 5.1.3.2.3. Chemotherapy
      • 5.1.3.2.4. Immunotherapy
      • 5.1.3.2.5. Others
    • 5.1.4. By End-users
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Ambulatory Surgical Centers
      • 5.1.4.3. Specialty Clinics
      • 5.1.4.4. Pharmacies
      • 5.1.4.5. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. Value
      • 5.1.5.1.2. Volume
      • 5.1.5.2. By Types
      • 5.1.5.2.1. Endometroid Adenocarcinoma
      • 5.1.5.2.2. Serous Adenocarcinoma
      • 5.1.5.2.3. Papillary Serous Carcinoma
      • 5.1.5.2.4. Uterine Sarcoma
      • 5.1.5.2.5. Others
      • 5.1.5.3. By Modality
      • 5.1.5.3.1. Diagnosis
      • 5.1.5.3.1.1. CT scan
      • 5.1.5.3.1.2. MRI Scan
      • 5.1.5.3.1.3. PET Scan
      • 5.1.5.3.1.4. Blood Test
      • 5.1.5.3.1.5. Ultrasound
      • 5.1.5.3.1.6. Endometrial Biopsy
      • 5.1.5.3.2. Treatment
      • 5.1.5.3.2.1. Surgery
      • 5.1.5.3.2.2. Radiation Therapy
      • 5.1.5.3.2.3. Chemotherapy
      • 5.1.5.3.2.4. Immunotherapy
      • 5.1.5.3.2.5. Others
      • 5.1.5.4. By End-users
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Ambulatory Surgical Centers
      • 5.1.5.4.3. Specialty Clinics
      • 5.1.5.4.4. Pharmacies
      • 5.1.5.4.5. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Types
  • 6.2. By Stages
  • 6.3. By Group
  • 6.4. By Modality
  • 6.5. By End-users
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. Merck & Co., Inc.
  • 13.4. Pfizer, Inc.
  • 13.5. AstraZeneca plc
  • 13.6. Johnson & Johnson Innovative Medicine
  • 13.7. Bayer AG
  • 13.8. AbbVie Inc.
  • 13.9. GSK plc
  • 13.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 3. Global Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 4. Global Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 5. Global Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 6. Global Uterine Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 9. North America Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 10. North America Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 11. North America Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 12. North America Uterine Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 15. United States Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 16. United States Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 17. United States Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 18. Canada Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 20. Canada Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 21. Canada Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 22. Canada Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 23. Mexico Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 25. Mexico Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 26. Mexico Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 27. Mexico Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 28. Europe Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 30. Europe Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 31. Europe Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 32. Europe Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 33. Europe Uterine Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 36. Germany Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 37. Germany Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 38. Germany Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 39. France Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 41. France Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 42. France Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 43. France Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 44. Italy Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 46. Italy Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 47. Italy Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 48. Italy Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 49. United Kingdom Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 51. United Kingdom Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 52. United Kingdom Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 53. United Kingdom Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 54. Russia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 56. Russia Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 57. Russia Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 58. Russia Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 59. Netherlands Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 61. Netherlands Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 62. Netherlands Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 63. Netherlands Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 64. Spain Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 66. Spain Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 67. Spain Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 68. Spain Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 69. Turkey Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 71. Turkey Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 72. Turkey Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 73. Turkey Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 74. Poland Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 76. Poland Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 77. Poland Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 78. Poland Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 79. South America Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 81. South America Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 82. South America Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 83. South America Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 84. South America Uterine Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 87. Brazil Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 88. Brazil Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 89. Brazil Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 90. Argentina Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 92. Argentina Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 93. Argentina Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 94. Argentina Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 95. Asia-Pacific Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 97. Asia-Pacific Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 98. Asia-Pacific Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 99. Asia-Pacific Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 100. Asia-Pacific Uterine Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. India Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 103. India Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 104. India Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 105. India Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 106. China Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 108. China Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 109. China Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 110. China Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 111. Japan Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 113. Japan Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 114. Japan Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 115. Japan Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 116. Australia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 118. Australia Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 119. Australia Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 120. Australia Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 121. Vietnam Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 123. Vietnam Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 124. Vietnam Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 125. Vietnam Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 126. South Korea Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 128. South Korea Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 129. South Korea Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 130. South Korea Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 131. Indonesia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 133. Indonesia Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 134. Indonesia Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 135. Indonesia Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 136. Philippines Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 138. Philippines Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 139. Philippines Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 140. Philippines Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 141. Middle East & Africa Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 143. Middle East & Africa Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 144. Middle East & Africa Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 145. Middle East & Africa Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 146. Middle East & Africa Uterine Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 149. Saudi Arabia Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 150. Saudi Arabia Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 151. Saudi Arabia Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 152. UAE Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 154. UAE Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 155. UAE Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 156. UAE Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 157. South Africa Uterine Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Uterine Cancer Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 159. South Africa Uterine Cancer Market Share (%), By Types, 2017-2031F
  • Figure 160. South Africa Uterine Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 161. South Africa Uterine Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 162. By Types Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023